Magenta Therapeutics Inc (NASDAQ:MGTA) insider Jason Gardner sold 11,200 shares of Magenta Therapeutics stock in a transaction on Friday, January 10th. The shares were sold at an average price of $15.25, for a total value of $170,800.00. Following the completion of the sale, the insider now directly owns 251,212 shares of the company’s stock, valued at approximately $3,830,983. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Jason Gardner also recently made the following trade(s):

  • On Monday, December 23rd, Jason Gardner sold 2,897 shares of Magenta Therapeutics stock. The shares were sold at an average price of $15.10, for a total value of $43,744.70.
  • On Tuesday, December 10th, Jason Gardner sold 4,392 shares of Magenta Therapeutics stock. The shares were sold at an average price of $15.10, for a total value of $66,319.20.

MGTA stock traded up $0.22 during trading on Friday, reaching $15.24. 78,163 shares of the stock traded hands, compared to its average volume of 98,709. The business’s 50 day moving average price is $13.99 and its 200-day moving average price is $12.09. Magenta Therapeutics Inc has a 52-week low of $5.65 and a 52-week high of $21.00. The firm has a market capitalization of $580.94 million, a PE ratio of -4.87 and a beta of 3.27.

Magenta Therapeutics (NASDAQ:MGTA) last posted its quarterly earnings results on Wednesday, November 13th. The company reported ($0.54) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.54). Equities research analysts anticipate that Magenta Therapeutics Inc will post -2.05 EPS for the current year.

MGTA has been the subject of a number of research reports. Zacks Investment Research downgraded Magenta Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 15th. Goldman Sachs Group reissued a “neutral” rating and set a $18.00 price target on shares of Magenta Therapeutics in a research report on Friday, December 6th. ValuEngine downgraded Magenta Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 20th. BTIG Research initiated coverage on Magenta Therapeutics in a research report on Friday, December 6th. They set a “buy” rating and a $20.00 price target for the company. Finally, Cowen reissued a “buy” rating on shares of Magenta Therapeutics in a research report on Monday, December 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $17.75.

Several institutional investors and hedge funds have recently modified their holdings of MGTA. Metropolitan Life Insurance Co NY acquired a new position in shares of Magenta Therapeutics during the third quarter worth about $76,000. JPMorgan Chase & Co. lifted its stake in shares of Magenta Therapeutics by 52.8% during the second quarter. JPMorgan Chase & Co. now owns 5,349 shares of the company’s stock worth $79,000 after purchasing an additional 1,848 shares in the last quarter. OneAscent Financial Services LLC acquired a new position in shares of Magenta Therapeutics during the second quarter worth about $166,000. Evoke Wealth LLC acquired a new position in shares of Magenta Therapeutics during the third quarter worth about $186,000. Finally, Virtus ETF Advisers LLC acquired a new position in shares of Magenta Therapeutics during the second quarter worth about $274,000. Institutional investors own 63.42% of the company’s stock.

Magenta Therapeutics Company Profile

Magenta Therapeutics, Inc, a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases.

Featured Article: Learning About the VIX – Volatility Index

Insider Buying and Selling by Quarter for Magenta Therapeutics (NASDAQ:MGTA)

Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.